SG RNA tech firm completes $390m Series D funding; applies for HKEX
Mirxes creates diagnostic solutions to early detect diseases.
Singapore-headquartered Mirxes Holding Company Limited secured $390m (US$50m) Series D funding.
It will play a pivotal role in speeding up Mirxes’ delivery of cancer early-detection blood tests and preventive healthcare solutions in major markets.
The funding was supported by investors including Beijing Fupu, which the Management Committee of Zhejiang Anji Economic Development Zone indirectly owned a majority stake in, EDB Investments Pte Ltd, wholly owned by the Singapore Economic Development Board, Agency for Science, Technology, and Research, Singapore’s lead public sector R&D agency for scientific discovery and technological innovation, Mitsui & Co., Ltd., a company listed on various stock exchanges in Japan, and NHH Venture Fund.
The fresh investment will be used to scale the adoption and penetration of Mirxes’s flagship stomach cancer blood test, GASTROClearTM, in major Asia-Pacific markets including Southeast Asia, the People’s Republic of China (PRC), and Japan.
Aside from the funding, Mirxes said it lodged a listing application with The Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX.
“The company's commitment to being a leading RNA-centric multi-omics technology company that provides accurate, accessible, and actionable diagnostic solutions to address critical unmet clinical needs across the care continuum has propelled it towards these milestones, which will provide enhanced opportunities for investors and further bolster Mirxes's global position,” read the statement.
This new investment will support Mirxes in its position to become a frontrunner in the fight against cancer through early detection.
“This fresh funding will fuel our ambitious growth plans and enable us to continue making a significant impact in the field of multi-cancer early detection,” said Mirxes CEO ZHOU Lihan.
$1 = US$0.13